KARIAN is responsible for the distribution and promotion of the COLCHICINA ACARPIA in Greece.
The diuretic, analgesic and anti-inflammatory properties of Colchicine have been known since antiquity. Colchicine, based on clinical trials and international guidelines, is the first choice for the treatment of gout, pericarditis, Mediterranean fever and Behcet’s disease, with official indication for gout.
The GRECCO-19 study is already being conducted by leading Greek doctors with the approval of EODY and the Ministry of Health for the use of colchicines in patients with COVID-19. At the same time, 3 other clinical trials are being conducted in Canada, neighboring Italy and Latin America on the use of colchicine in patients with COVID-19.
We thank you for the trust you show in COLCHICINA ACARPIA, the original & unique colchicine in the Greek Pharmaceutical Market and we will make every effort to meet market needs.
At your disposal for more information.
ADDITIONAL DATA FOR THE USE OF COLCHICINA IN COVID-19
Based on the researchers’ reasoning, colchicine with its strong anti-inflammatory action, excellent results in clinical trials, especially in cardiology, the recommendations of international scientific bodies and extensive clinical experience can be a protective factor for the development of the disease in patients who suffer from COVIC-19 and reduce complications in the heart and lungs by improving the patient’s prognosis and reducing the number of intubations and deaths.
At the same time, 3 other clinical trials are being conducted in Canada, Italy and Latin America on the use of colchicine in patients with COVID-19.
You can find more information at the following addresses:
1. ITALY, PHASE 2: https://clinicaltrials.gov/ct2/show/NCT04322565
2. CANADA, PHASE 3: https://clinicaltrials.gov/ct2/show/NCT04322682
3. LATIN AMERICA, PHASE 3: https://clinicaltrials.gov/ct2/show/NCT04328480
Coronavirus: Colchicine, the Greek proposal in the fight against virus
It is a well-known drug with anti-inflammatory properties, used to treat many diseases – Submitted by research team at EODY
Long research group led by Professor Cardiology n. Spiro Deftereos, filed research proposal to PHEA on the use of a known drug, colchicine for the treatment of patients from disease coronavirus (COVID-19).
The research protocol involves a large number of distinguished Greek and foreign scientists, from the field of Infectious Diseases, Cardiology, Epidemiology, Pulmonology and Intensive Care, as shown below:
GRECCO-19 study (The Greek study of the effects of Colchicine in Covid-19 complications prevention)
Spyridon C. Deftereos, Gerasimos LEFKOSIA Georgios Giannopoulos Dimitrios A.. Vrahatis Christos Angelides Salvation III. Giotaki Panagiotis Gargalianos Helen Giamarellou Charalambos Gogos Georgios Saiki, Marios lasagne, Pagona Lagiou, George Saroglou Nikolaos Sypsas, Sotirios Tsiodras , Dimitrios Hatzigeorgiou, Nikolaos Moussas, Anastasia Kotanidou, Nikolaos Koulouris, Evangelos Ikonomou, Andreas Koukis, Charalambos Kosivakis, Konstantinos Raisakis, Katerina Fountoulis, Michiris Echmiakis We, Luis Martinez-Dolz, Sanz-Sánchez Jorge, Bernhard Reimers, Giulio G. Stefanini, Michael Cleman, Dimitrios Filippou, Christopher D. Olympios, Vlasios N. Pyrgakis, Ioannis Goudevenos, Georgios Chachalis, Theophilos Itholis, Theofilos Ioannis. Dimitrios Tousoulis, Christodoulos Stefanadis.
Department of Cardiovascular Medicine – Yale University, USA
Responsible: Prof. Michael Cleman
Department of Cardiovascular Medicine, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy
Managers: Dr. Bernhard Reimers (Director), Prof. Giulio Stefanini
Cardiology Department, Hospital Universitario y Politécnico La Fe
University of Valencia. Valencia (Spain)
Responsible: Luis Martinez Dolz MD, PhD, FESC (Director, Ass. Prof)
Colchicine is a well-known drug with anti-inflammatory and other unique properties, used to treat many diseases, such as gout, Mediterranean fever, pericarditis and others.
Over the past 10 years, S. Deuteraios, H. Stefanadis and M. Cleman (from Yale University) have expanded the indications and used colchicine successfully in the treatment of atrial fibrillation, acute myocardial infarction, and in the treatment of stenting , publishing research results in top international scientific journals.
This research protocol has been unanimously approved by the relevant EODY committee, and the clinical trial will begin immediately.
The seriousness of the hypothesis that colchicine is likely to have a positive therapeutic effect in patients with coronavirus (COVID 19) is strongly supported by the fact that after the Greek research team, and a Canadian research team, are preparing to administer the drug to 6,000 people positive for the virus, having announced a protocol.
Message on behalf of Armando De Vincentiis, Medical Director of Acarpia Farmaceutici srl
The scientific community, strongly committed in his battle against Covid-19 pandemic, is turning his attention also to a potential role that colchicine could exert in the treatment of patients with mild symptoms.
In fact, the Canadian government just started an extensive clinical trial, coordinated by Dr. Tardif, that will involve 6.000 patients.
“I have no evidence that it will work. But if it works, and I agree it’s a big deal, we can dream. If you no longer fear, or much less, the severe complications of COVID-19, that changes everything. We no longer need to lock people up and quarantine them. We are faced with a disease which is altogether banal. It just transformed the world scene instantly.” says Dr. Tardif.
Other smaller experiences are beginning elsewhere.
We hope that these studies will be useful to the patients and increase our knowledge about colchicine, and we hope it will be significant in enabling the progress of medicine.
Researchers study drug to reduce COVID-19 complications
Issued on:23/03/2020 -17:52Modified:23/03/2020 -17:51
Canadian researchers launched a study Monday into the use of a powerful anti-inflammatory drug to reduce the risks of pulmonary complications and death related to the new coronavirus.
Several COVID-19 patients have had severe complications from a surge of activated immune cells in the lungs –known as a “cytokine storm.”
In a cytokine storm, the immune system overreacts and damages lung tissue, leading to acute respiratory distress and multi-organ failure.
A team led by Jean-Claude Tardif, director of the Montreal Heart Institute research center and professor of medicine at the University of Montreal, are hoping the drug colchicine will work to moderate the overproduction of immune cells and their activating compounds –called cytokines –in COVID-19 patients.
If it proves to be successful, the drug –which is already used to treat gout and pericarditis (inflammation of the heart membrane), and is readily available and inexpensive –could become a key tool in the pandemic fight.